SCHOFIELD, Wis., Oct. 15, 2014 /PRNewswire/ -- PuraMed
BioScience®, Inc., (OTCPink: PMBSD), a researcher,
developer, and marketer of over-the-counter medicinal and
healthcare products, announced that Ludlow Research has issued a
research opinion of the Company based on the pending launch of its
rebranded migraine product, MigraPure, the development of a
hemp-based epilepsy symptom treatment, and the Company's current
valuation.
The Company recently announced development of an
over-the-counter medication using cannabinoid-rich hemp, for the
treatment of epilepsy symptoms. Recent studies show CBD to be
effective in the treatment of the symptoms of epilepsy.
"As PuraMed prepares to re-launch its natural over-the-counter
migraine product as MigraPure and develops its hemp-based
formulation, the company could create a medication with wide
ranging benefits for people who suffer with epilepsy and who suffer
chronic migraines," said Tom
Bustamonte, of Ludlow Research.
In addition, the Company recently announced completion of the
first batch of its patented, sublingual MigraPure®
Advanced Migraine Relief feverfew and ginger gel with an enhanced
flavor.
MigraPure Advanced Migraine Relief is a doctor-recommended
homeopathic formulation that has been clinically tested
(originally tested as LipiGesic® M) by headache
experts and found highly effective in the treatment of acute
migraine pain and associated symptoms. Packaged in pre-measured
UnitDose sachets, MigraPure's gel is administered under the tongue,
which allows active ingredients to reach the bloodstream faster and
more effectively than traditional oral medications.
PMBSD current has approximately 70 million common shares issued
and outstanding, and is fully reporting with the SEC.
Ludlow Research issued their "speculative" opinion on PMBSD
based on research in areas of epilepsy symptom treatment using
cannabinoid-rich hemp, the pending re-launch of the
over-the-counter migraine product, MigraPure advanced migraine
relief, and the current low market cap value of the Company, which
is just under $300,000.
To download the full report, and access risks, disclosers, and
potential outlook visit www.ludlowresearch.com/reports.html
About Ludlow Research
Ludlow Equity Research is a New
York based equity research firm focused on providing our
clients, and individual readers, with in-depth research coverage
and opinions on the small-cap securities market. For over 14 years,
we have aimed to provide our subscribers a simple way of evaluating
the current and potential value of small-cap stocks, and any risks
that may affect those valuations going forward. Our goal is to
provide traders with an easy way to make investment decisions based
on current and future valuations. Ludlow Equity Research is a
division of Ludlow Capital, Inc. www.ludlowresearch.com
Ludlow Research provides research coverage and host of investor
awareness services for publicly traded small cap equities.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and
marketing of non-prescription medicinal and healthcare products,
which often work faster, more effectively, and have fewer side
effects than their chemical-based counterparts.
In addition to the rebranding of LipiGesic M as MigraPure, PMBS
plans to launch additional hemp-based, cannabinoid-enhanced,
anti-inflammatory and anxiolytic products as it moves forward in
the development of its cannabinoid product line.
www.PuramedBioScience.com
Forward-Looking Statements
This news release contains forward-looking statements regarding
PuraMed BioScience, Inc., and its future business plans, which
statements involve known and unknown risks and uncertainties. Such
risks and uncertainties may cause actual results and future
achievements of PuraMed BioScience to be materially different from
those implied by these forward-looking statements. PuraMed
BioScience has and undertakes no obligation to provide public
updates and revisions to these forward-looking statements to
reflect any changes in its expectations of future events.
Contacts:
Russ Mitchell
PuraMed BioScience, Inc.
715.359.6373
Melissa J. Diaz
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com
SOURCE PuraMed BioScience, Inc.